中国实用外科杂志2023，Vol.43Issue(12)：1422-1428,7.DOI:10.19538/j.cjps.issn1005-2208.2023.12.20
原发性甲状腺淋巴瘤临床预后相关因素及生存研究
Clinical prognostic factors and survival study of primary thyroid lymphoma:a single-center retrospective study
摘要
Abstract
Objective To analyze the clinical features of primary thyroid lymphoma(PTL)and the related factors of pri-mary thyroid diffuse large B cell lymphoma(PTDLBCL)affecting overall survival(OS)and progression-free survival(PFS).Methods The clinical data of 74 patients with PTL who were diagnosed with Ann Arbor stage ⅠE-ⅡE in the First Affiliated Hospital of Zhengzhou University from 2011 to 2022 were retrospectively collected.A descriptive analysis was carried out on the clinical features,treatment,and follow-up.54 patients with PTDLBCL were subjected to prognos-tic univariate analysis and multivariate analysis.Kaplan-Meier method and Log-rank test were used for univariate analy-sis and multivariate analysis using the Cox proportional hazards regression model.Results The median follow-up time of 74 PTL patients was 26 months(range,1-117 months),and the 1-year,3-year,and 5-year OS were 85.0％,78.4％,and 75.6％;the 1-year,3-year,and 5-year PFS were 76.5％,71.7％,and 63.1％.Multivariate analysis shows that the use of anti-CD20 monoclonal antibody(P=0.020)is a protective factor for OS in patients with PTDLBCL;chemotherapy-based combined treatment with surgery or radiotherapy(P=0.046),and treatment with anti-CD20 monoclonal antibody(P=0.003)are the protective factors for PFS.Conclusion The main pathological type of PTL is DLBCL.For PTDLBCL patients,therapy with anti-CD20 monoclonal antibody is more beneficial to improve the OS and PFS,comprehensive treatment with chemotherapy as the main treatment can help prolong the PFS.关键词
原发性甲状腺淋巴瘤/弥漫大B细胞淋巴瘤/预后/无进展生存期Key words
primary thyroid lymphoma/diffuse large B-cell lymphoma/prognosis/progression-free survival分类
医药卫生引用本文复制引用
赵海鑫,耿祖仕,卢秀波..原发性甲状腺淋巴瘤临床预后相关因素及生存研究[J].中国实用外科杂志,2023,43(12):1422-1428,7.基金项目
河南省卫生健康中青年学科带头人项目(No.HNSWJW-2020004) （No.HNSWJW-2020004）
